SOPH vs. ARDX, NTLA, ZYME, LENZ, CVAC, CRMD, CMRX, CDMO, CRON, and XERS
Should you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Ardelyx (ARDX), Intellia Therapeutics (NTLA), Zymeworks (ZYME), LENZ Therapeutics (LENZ), CureVac (CVAC), CorMedix (CRMD), Chimerix (CMRX), Avid Bioservices (CDMO), Cronos Group (CRON), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.
SOPHiA GENETICS vs.
Ardelyx (NASDAQ:ARDX) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, community ranking, analyst recommendations, media sentiment, profitability, risk and earnings.
Ardelyx has higher revenue and earnings than SOPHiA GENETICS. Ardelyx is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ardelyx had 12 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 12 mentions for Ardelyx and 0 mentions for SOPHiA GENETICS. Ardelyx's average media sentiment score of 0.85 beat SOPHiA GENETICS's score of 0.00 indicating that Ardelyx is being referred to more favorably in the media.
58.9% of Ardelyx shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 4.8% of Ardelyx shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Ardelyx presently has a consensus price target of $10.39, indicating a potential upside of 159.40%. SOPHiA GENETICS has a consensus price target of $6.80, indicating a potential upside of 127.42%. Given Ardelyx's stronger consensus rating and higher possible upside, equities analysts clearly believe Ardelyx is more favorable than SOPHiA GENETICS.
Ardelyx received 520 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 70.37% of users gave SOPHiA GENETICS an outperform vote while only 67.46% of users gave Ardelyx an outperform vote.
Ardelyx has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
Ardelyx has a net margin of -11.73% compared to SOPHiA GENETICS's net margin of -110.71%. Ardelyx's return on equity of -24.87% beat SOPHiA GENETICS's return on equity.
Summary
Ardelyx beats SOPHiA GENETICS on 14 of the 19 factors compared between the two stocks.
Get SOPHiA GENETICS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SOPHiA GENETICS Competitors List
Related Companies and Tools
This page (NASDAQ:SOPH) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy SOPH Stock Free SOPH Stock Alerts